Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis
Impact of time-of-day administration of immunotherapy on survival in metastatic renal cellcarcinoma: the MOUSEION-09 meta-analysis
Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study
Sex differences in adverse events among cancer patients receiving immune checkpointinhibitors: the MOUSEION-07 systematic review and meta-analysis
The impact of ECOG performance status on efficacy of immunotherapy and immune-basedcombinations in cancer patients: the MOUSEION-06 study
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-basedcombinations: the MOUSEION-05 study
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: TheMOUSEION-04 Study
Complete remissions following immunotherapy or immuno-oncology combinations incancer patients: the MOUSEION-03 meta-analysis
Peripheral neuropathy and headache in cancer patients treated with immunotherapy andimmuno-oncology combinations: the MOUSEION-02 study
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients:The MOUSEION-01 study
